|
Global HTA Models
YHEC specialises in the development of global models for purposes of health technology assessment. Such models have been carried out in a wide range of disease areas, and have been submitted to NICE, the SMC and the AWMSG. Our models have also been adapted for submission to all major European markets, North America, Australia and the Far East.
All of our core global models are designed to meet the requirements of international HTA bodies. The models are designed to reflect a range of potential treatment pathways and are designed to allow for easy adaptation to other settings. Whilst the type of model varies by disease area, our global models have included patient simulation models, Markov models, decision trees, and economic analyses alongside clinical trials.
Some of our recent publications are:
Hutton, J. Mixed palette Pharmaceutical Marketing Update 2010; July/August : 24-26.  Stamuli E, Kruger J, Hutton J. Cost-effectiveness of ultrasound elastography in the assessment of liver fibrosis Centre for Evidence-Based Purchasing Economic Report CEP08053 2009; February. Brown P, Brunnhuber K, Chalkidou K, Chalmers I, Clarke M, Fenton M, Forbes C, Glanville J, Hicks NJ, Moody J, Twaddle S, Timimi H, Young P. How to formulate research recommendations BMJ 2006; 333: 804-6. Téot L, Cherry G, Denis C, Dervaux B, Duncan G, Gottrup F, Harding K, Kerihuel JC, Lautenberg A, Mani R, Meaume S, Messina R, Morris S, Orsted H, Pavlovic M, Peter R, Ricci E, Sibbald G, Sussmann G, Trueman P, World Union of Wound Healing Societies. Reimbursement of dressings: a WUWHS statement International Wound Journal 2006; 3(4) December: 296-301. Sheldon TA, Cullum N, Dawson D, Lankshear A, Lowson KV, Watt I, West PA, Wright DL, Wright J. What's the evidence that NICE guidance has been implemented? Results from a national evaluation using time series analysis, audit of patients; notes, and interviews BMJ 2004; 329: 999. Bagust A, Shearer A, Schoeffski O, Reitberger U, Goertz A, Behrens M. Cost-effectiveness in Germany of rosiglitazone-metformin combination in type 2 diabetes Diabetologia 2003; 46(Suppl 2): A444.
For more details please contact Dr Matthew Taylor (Project Director, Pharmacoeconomics) by telephone (+44 (0) 1904 323631) or email (matthew.taylor@york.ac.uk)
|
